QX-4533 not checked

QuantX Biosciences US Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“QX-4533 placebo, an oral investigational drug, administered as oral tablets in single or repeated dose escalation schedules for moderate-to-severe atopic dermatitis patients and healthy volunteers”In the company’s words, NCT07800104 on ClinicalTrials.gov
Tested for
Atopic Dermatitis
Main trialPhase 1
“The primary purpose of this study is to evaluate the safety and tolerability of QX-4533 following oral administration of single and multiple ascending doses in healthy participants.”In the company’s words, NCT07678463 on ClinicalTrials.gov

Other drugs for Atopic Dermatitis

All 90 drugs for Atopic Dermatitis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 25 Dec 2026 A Single and Multiple Ascending Dose Escalation and Food Effect Study of QX-4533 in Healthy Participants
Phase 1Recruiting 14 Apr 2027 Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow QX-4533

Following is part of Solo: you see every change to QX-4533 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in